MDACC Study No:2011-0041 ( NCT No: NCT01390337)
Title:A Phase 1 Study of AC220 (ASP2689) in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia
Principal Investigator:Jorge Cortes
Treatment Agent:AC220; Cytarabine; Daunorubicin
Study Status:Closed
Study Description:The goal of this clinical research study is to learn the highest tolerable dose
and best schedule of the combination of up to 2 cycles of Induction
chemotherapy (daunorubicin, cytarabine, and AC220), up to 3 cycles of
Consolidation chemotherapy (AC220 and high dose cytarabine), and then up to 12
cycles of Maintenance chemotherapy (AC220) that can be given to patients with
AML. The safety of this combination of drugs will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I
Treatment Agents:AC220
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Astellas Pharma Global Development, Inc. (APGD)
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jorge Cortes
For Clinical Trial Enrollment:713-794-5783
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults